{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002855","form_type":"8-K","ticker":"SENS","cik":"0001616543","company_name":"Senseonics Holdings, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.200135+00:00","generated_at":"2026-05-28T03:23:43.827749+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Senseonics reports preliminary 2024 revenue of $22.5M, patient base up 56%, cancels reverse stock split meeting","bullets":["Preliminary Q4 revenue ~$8.3M; full year 2024 revenue ~$22.5M.","Patient base grew 56% to ~6,000 global patients; over 1,000 US prescribers in 2024.","December new patient shipments ~600, highest monthly total; DTC leads doubled in Q4.","Cash, equivalents, restricted cash ~$74.9M at Dec 31, 2024; operating expenses guided.","Cancelled special meeting for reverse stock split after share price appreciation; proxies favored split."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002855","json":"https://secwatch.observer/filing/0001104659-25-002855.json","markdown":"https://secwatch.observer/filing/0001104659-25-002855.md","text":"https://secwatch.observer/filing/0001104659-25-002855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616543/000110465925002855/0001104659-25-002855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616543/000110465925002855/tm252718d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:23:43.827749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}